Skip to main content

Advertisement

Log in

Development of visceral leishmaniasis in an HIV+ patient upon immune reconstitution following the initiation of antiretroviral therapy

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Case presentation

Here, we report on a case of VL in an HIV-infected patient from the Republic of Georgia who had moved to Germany 14 years before and who had travelled several times to southern Europe in between. After presenting with typical Pneumocystis jiroveci pneumonia, which was treated appropriately, the patient was started on antiretroviral therapy. Shortly thereafter, however, he developed fever of unknown origin. All laboratory assays for the diagnosis of various infectious agents including serological assays and polymerase chain reaction testing of bone marrow aspirate to diagnose VL did not yield positive results at first. Only upon repetition of these tests, diagnosis of VL could be made and the patient treated accordingly.

Case discussion

Visceral leishmaniasis (VL) is a common opportunistic infection in HIV-positive patients from endemic countries but occurs rarely following antiretroviral treatment. This case demonstrates that patients who develop VL upon immune reconstitution may not be diagnosed initially by standard laboratory assays for the diagnosis of VL and underlines the necessity to repeat serologic and molecular biologic testing for VL in cases of fever of unknown origin in patients from or with travel history to endemic countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Schonian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HD, Presber W, Jaffe CL. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis. 2003;47:349–58.

    Article  CAS  PubMed  Google Scholar 

  2. Mussini C, Manzardo C, Johnson M, Monforte A, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS. 2008;22:2461–9.

    Article  PubMed  Google Scholar 

  3. Mosimann V, Neumayr A, Hatz C, Blum JA. Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment. Infection. 2013;41:1177–82.

    Article  CAS  PubMed  Google Scholar 

  4. Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, Silva RM Jr, Ferreira LC, Botileiro SF, Santos LO, Dietze R, Talhari S. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg. 2009;81:559–64.

    Article  CAS  PubMed  Google Scholar 

  5. Leishmaniasis Fact sheet N°375. http://www.who.int/mediacentre/factsheets/fs375/en/.

  6. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21:334–59 table of contents.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Gil-Prieto R, Walter S, Alvar J, de Miguel AG. Epidemiology of leishmaniasis in Spain based on hospitalization records (1997–2008). Am J Trop Med Hyg. 2011;85:820–5.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Albrecht H, Sobottka I, Emminger C, Jablonowski H, Just G, Stoehr A, Kubin T, Salzberger B, Lutz T, van Lunzen J. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med. 1996;120:189–98.

    CAS  PubMed  Google Scholar 

  9. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore). 2001;80:54–73.

    Article  CAS  Google Scholar 

  10. Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis. 2007;20:482–8.

    Article  PubMed  Google Scholar 

  11. Badaro R, Goncalves LO, Gois LL, Maia ZP, Benson C, Grassi MF. Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients: A literature review. J Int Assoc Provid AIDS Care. 2014;1:1.

    Google Scholar 

  12. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57:167–70.

    Article  CAS  PubMed  Google Scholar 

  13. Thoden J, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Harter G, Hartmann M, et al. Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/OAG) (AWMF 055/066). Infection. 2013;41(Suppl 2):S91–115.

    Article  PubMed  Google Scholar 

  14. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, Bohjanen PR, Sungkanuparph S, Easterbrook PJ, French MA, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10:791–802.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Feurle GE, Moos V, Schinnerling K, Geelhaar A, Allers K, Biagi F, Blaker H, Moter A, Loddenkemper C, Jansen A, Schneider T. The immune reconstitution inflammatory syndrome in whipple disease: a cohort study. Ann Intern Med. 2010;153:710–7.

    Article  PubMed  Google Scholar 

  16. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18:1615–27.

    Article  CAS  PubMed  Google Scholar 

  17. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis. 2008;46:1702–9.

    Article  PubMed  Google Scholar 

  18. de la Rosa R, Pineda JA, Delgado J, Macias J, Morillas F, Martin-Sanchez J, Leal M, Sanchez-Quijano A, Lissen E. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis. 2001;32:633–5.

    Article  PubMed  Google Scholar 

  19. Brotherton MC, Bourassa S, Legare D, Poirier GG, Droit A, Ouellette M. Quantitative proteomic analysis of amphotericin B resistance in Leishmania infantum. Int J Parasitol Drugs Drug Resist. 2014;4:126–32.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

MP and BS were supported by a grant from the German Ministry of Education and Research (grant numbers 01KI1204).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Benjamin T. Schleenvoigt.

Ethics declarations

Conflict of interest

None for all authors.

Consent

Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schleenvoigt, B.T., Ignatius, R., Baier, M. et al. Development of visceral leishmaniasis in an HIV+ patient upon immune reconstitution following the initiation of antiretroviral therapy. Infection 44, 115–119 (2016). https://doi.org/10.1007/s15010-015-0813-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-015-0813-7

Keywords

Navigation